NAIA RELIEF INC
0.57
CAD
-0.09
(-13.64%)
ISIN
CA62881H1064
CUSIP
62881H106
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CAD
•
in mil. unless spec.Working Capital
CAD
•
in mil. unless spec.Growth Rates
CAD
•
in mil. unless spec.Quarterly Revenue
CAD
•
in mil. unless spec.Quarterly Earnings Per Share
CAD
•
in mil. unless spec.Quarterly Dividends Per Share
CAD
•
in mil. unless spec.Company Description
- CEO
- Jennifer Thor
- Sector
- Technology services
- Industry
- Packaged software
- Address
- Vancouver Canada
- Similar Companies
- Business
- Naia Relief, Inc. operates as a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutic solutions for rare gastrointestinal disorders, pediatric metabolic conditions, and orphan diseases. The company's core product development pipeline comprises GLP-2 receptor agonist peptide therapeutics engineered for the treatment of short bowel syndrome and chronic intestinal failure; targeted mucosal barrier repair compounds designed to manage severe malabsorption and gut inflammation; small-molecule therapeutic candidates for pediatric gastrointestinal motility disorders; and proprietary extended-release peptide formulations for specialized endocrine and metabolic indications. Naia Relief, Inc. targets healthcare providers, specialized clinical centers, and patient populations across North America and Europe. Founded in 2015 and headquartered in Vancouver, Canada, the company conducts its translational research, preclinical evaluations, and clinical trial programs in partnership with international contract research organizations and academic medical institutions. In recent corporate developments, Naia Relief, Inc. completed equity financing rounds to fund the progression of its lead clinical candidates through mid-stage clinical trials, entered into strategic research and licensing collaborations to expand its rare disease therapeutic portfolio, implemented operational restructuring initiatives to prioritize resource allocation toward core gastrointestinal programs, and secured additional intellectual property protections through international patent grants covering its peptide delivery technologies.